Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
|Articles|October 14, 2022
News Roundup: October 10 to October 14
Author(s)Miranda Hester
Your weekly roundup of the latest news from Drug Topics®.
Advertisement
Stelara Study Shows Efficacy for Ulcerative Colitis
Clinical trial results reported at United European Gastroenterology Week 2022 highlight Stelara's effectiveness.
Spotlight on Mental Health: World Mental Health Day 2022
Make mental health a priority.
Seqirus Receives Government Contract to Develop 2 Flu Vaccines
The vaccines will utilize the company’s technology in a bid to protect against pandemic influenza.
Closing the Historic Routine-Vaccination Gap
Pharmacists can play a key role in helping to improve backsliding vaccination rates.
Industry Trends: What to Watch For
From biosimilars to artificial intelligence, these are the trends poised to take community pharmacy by storm.
Advertisement
Related to this article
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
Cheri Schmit explains how pharmacists' roles are growing beyond dispensing into prevention, test-and-treat, and artificial intelligence-supported patient care.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
PBM Network Terminations Bring Risks Beyond Lost Contracts | NCPA 2026
3
FAQ: Scaling Pharmacy Services Through GLP-1 Care | NCPA 2026
4
Pharmacists Step Up on Test-To-Treat This American Pharmacist Month
5